Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2618 Plus Toripalimab in Advanced Melanoma
NCT05451407Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2618 in melanoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity at 21 days, Phase II Recommended Dose at 21 days and 1 more. Status: unknown.
02
Drugs
TQB2618
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05451407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451407.